Mercks anti PD 1 trial

Posted By
11/26/2011 1:03am
View other posts by
Activity
Replies: 5

Trial Information

Study of MK-3475 in Participants With Progressively Locally Advanced or Metastatic Carcinomas & Melanoma (P07990/MK-3475-001 AM2)

Official Title: Phase I Study of Single Agent MK-3475 in Patients With Progressively Locally Advanced or Metastatic Carcinomas & Melanoma

Summary

In Part A of this study, the dose of intravenous (IV) MK-3475 will be escalated to find the maximum tolerated dose (MTD) for participants with a histologically or cytologically confirmed diagnosis of any type of carcinoma or melanoma (MEL). Part B of the study will explore the efficacy of the drug at the MTD in participants with advanced or metastatic MEL.

Phase: Phase 1

Locations (1)

Country
State
City
Zip
Facility and Contact

United States
Texas
San Antonio
78229
Investigational Site 1

Overall Contacts

SP Clinical Trial Registry Call Center
1-888-772-8734

NCT ID:NCT01295827

Date Last Changed: October 21, 2011

Advocate for your own treatment.. Stage 4 Melanoma NED Surgery,Radiation, Temodar 300Mg July 2009-March 2010, then Thorocotomy...now "Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy"

LynnLuc - (11/26/2011 - 1:17am)

Advocate for your own treatment.. Stage 4 Melanoma NED Surgery,Radiation, Temodar 300Mg July 2009-March 2010, then Thorocotomy...now "Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy"

MariaH - (11/28/2011 - 8:00am)

Thanks for posting Lynn!

chet - (11/28/2011 - 8:45pm)

Sorry if this is a dumb question, but  is MK-3475 the same thing as Anti PD1? I was going to enter into the clinical trial at MD Anderson for the E7080 drug but was wondering if I should switch to this one instead. 

“The secret of health for both mind and body is not to mourn for the past, worry about the future, or anticipate troubles, but to live in the present moment wisely and earnestly.” — Buddha

LynnLuc - (11/28/2011 - 11:27pm)

this link ought to help....http://citninfo.org/news/Anti-PD1/Craig_slides_for_pre-reading_material__SHORT.pdf    

 

 

 

 

 

E7080 E

Advocate for your own treatment.. Stage 4 Melanoma NED Surgery,Radiation, Temodar 300Mg July 2009-March 2010, then Thorocotomy...now "Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy"

LynnLuc - (11/28/2011 - 11:40pm)

I don't know why the font is so big lol...
When I had my Immunophenotype Report done, It said among other findings, like I was uniformly positive for HMB45 ( gp100), MART! (Melan A) and Tyrosinase.
I am in a vaccine trial ( Anti PD-1 and peptides) and the peptides were specific to the gp100 and Mart1….. Tyrosinase was not a part of my peptides, so it wold be interesting to see how this treatment works with Tyrosinase positive patients…could be my plan B or C.
I did find this…
Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.

Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø.

Source

Department of Tumour Biology, Institute for Cancer Research University in Oslo, Oslo, Norway. skjalg.bruheim@rr-research.no

Abstract

E7080 is an inhibitor of multiple tyrosine kinases, several of which have pro-angiogenic properties, including receptors for VEGF, FGF, SCF and PDGF. We undertook our study to evaluate the preclinical activity of E7080 in human sarcomas. The antitumour activity of orally administered E7080 was tested in ten human tumour xenografts representing different sarcoma histotypes. Concomitant changes in microvessel density were assayed by immunohistochemistry to CD31. Immunohistochemistry was also used to assess the expression of kinases that E7080 is known to inhibit. The MTS assay was applied to determine effects on tumour cell viability in vitro. At the Q1D5 × 2 schedule, E7080 (30 mg/kg) was active (T/C<40%) in 7/10 xenografts. The effects were accompanied by marked decrease in microvessel densities. Given at the Q1D5 × 4 schedule, E7080 (30, 10, 3 mg/kg) showed antitumour activity in a dose dependent manner in two different xenografts. E7080 growth inhibition did not correlate with the expression of VEGFR1-3, PDGFRA, PDGFRB, FGFR1 or KIT on tumour cells but was significantly correlated with expression of VEGFR2 on tumour microvessels. In vitro E7080 did not show potent effects on tumour cell viability in four different sarcoma cell lines, with IC50 values ≥ 10 μM. In conclusion, E7080 showed broad in vivo antitumour activity in sarcoma, mainly attributable to angiogenesis inhibition. E7080 was also active in xenografts resistant to one or more clinically relevant reference drugs given at MTD (doxorubicin, cisplatin or ifosfamide). The present results encourage further investigation of a potential role of E7080 in sarcoma therapy in the clinic.

Copyright © 2011 UICC.

Advocate for your own treatment.. Stage 4 Melanoma NED Surgery,Radiation, Temodar 300Mg July 2009-March 2010, then Thorocotomy...now "Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy"